Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

Lessons Learned The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of...

Full description

Bibliographic Details

Published in:	The oncologist (Dayton, Ohio) Vol. 23; no. 6; pp. 654 - e58
Main Authors:	von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Format:	Journal Article
Language:	English
Published:	United States AlphaMed Press 01.06.2018
Subjects:	Clinical Trial Results
ISSN:	1083-7159, 1549-490X, 1549-490X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!